Free Trial

Haemonetics (HAE) Competitors

Haemonetics logo
$77.79 +1.82 (+2.40%)
Closing price 07/9/2025 03:57 PM Eastern
Extended Trading
$77.49 -0.30 (-0.39%)
As of 08:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HAE vs. DXCM, HQY, LNTH, PODD, QTRX, SIBN, PEN, ZBH, ALGN, and MMSI

Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), Quanterix (QTRX), SiBone (SIBN), Penumbra (PEN), Zimmer Biomet (ZBH), Align Technology (ALGN), and Merit Medical Systems (MMSI). These companies are all part of the "medical" sector.

Haemonetics vs. Its Competitors

DexCom (NASDAQ:DXCM) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, DexCom had 15 more articles in the media than Haemonetics. MarketBeat recorded 22 mentions for DexCom and 7 mentions for Haemonetics. DexCom's average media sentiment score of 1.35 beat Haemonetics' score of 1.27 indicating that DexCom is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DexCom
18 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Haemonetics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$4.03B8.25$576.20M$1.3463.34
Haemonetics$1.36B2.75$167.68M$3.3123.50

DexCom presently has a consensus price target of $98.50, suggesting a potential upside of 16.06%. Haemonetics has a consensus price target of $97.30, suggesting a potential upside of 25.08%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than DexCom.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom
0 Sell rating(s)
4 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.95
Haemonetics
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.00

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 1.8% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DexCom has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

DexCom has a net margin of 12.90% compared to Haemonetics' net margin of 12.32%. DexCom's return on equity of 30.05% beat Haemonetics' return on equity.

Company Net Margins Return on Equity Return on Assets
DexCom12.90% 30.05% 10.00%
Haemonetics 12.32%26.37%9.22%

Summary

DexCom beats Haemonetics on 12 of the 17 factors compared between the two stocks.

Get Haemonetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HAE vs. The Competition

MetricHaemoneticsMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$3.65B$10.41B$5.51B$20.49B
Dividend YieldN/A2.09%5.25%3.74%
P/E Ratio23.5016.4028.0227.90
Price / Sales2.7531.20417.6739.35
Price / Cash10.5422.7937.0622.25
Price / Book4.763.728.144.59
Net Income$167.68M$235.43M$3.16B$982.91M
7 Day Performance1.23%2.31%3.16%0.11%
1 Month Performance7.78%2.59%3.49%3.55%
1 Year Performance-10.65%-10.94%34.22%13.79%

Haemonetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HAE
Haemonetics
4.8774 of 5 stars
$77.79
+2.4%
$97.30
+25.1%
-7.7%$3.65B$1.36B23.503,023News Coverage
Positive News
Analyst Upgrade
Gap Up
DXCM
DexCom
4.8727 of 5 stars
$87.29
+1.1%
$98.50
+12.8%
-23.4%$33.85B$4.03B65.1410,300Positive News
HQY
HealthEquity
3.7285 of 5 stars
$104.76
-0.1%
$118.09
+12.7%
+22.4%$9.07B$1.20B39.733,120Analyst Forecast
Insider Trade
LNTH
Lantheus
4.4537 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
+7.5%$5.64B$1.53B14.22700
PODD
Insulet
4.1244 of 5 stars
$314.18
+0.4%
$321.00
+2.2%
+52.4%$22.03B$2.07B56.513,900Positive News
Analyst Forecast
QTRX
Quanterix
2.4893 of 5 stars
$6.65
flat
$15.60
+134.6%
-53.4%$332.20M$137.42M0.00460
SIBN
SiBone
4.031 of 5 stars
$18.82
+2.1%
$22.50
+19.6%
+37.1%$785.39M$167.18M0.00350News Coverage
Positive News
PEN
Penumbra
4.8352 of 5 stars
$256.00
-0.2%
$302.40
+18.1%
+37.1%$9.93B$1.19B77.944,500Analyst Forecast
ZBH
Zimmer Biomet
4.9257 of 5 stars
$91.23
-0.3%
$111.53
+22.2%
-10.0%$18.10B$7.68B11.6217,000Positive News
Analyst Forecast
ALGN
Align Technology
4.5377 of 5 stars
$189.33
+0.4%
$241.25
+27.4%
-19.0%$13.66B$4.00B34.4920,945Positive News
Analyst Forecast
MMSI
Merit Medical Systems
4.392 of 5 stars
$93.48
0.0%
$109.11
+16.7%
+11.7%$5.53B$1.36B45.827,400Analyst Forecast

Related Companies and Tools


This page (NYSE:HAE) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners